October 17, 2025Open Access

Supplementary Figure 3 from Concordance between Tumor Tissue and Plasma DNA Genotyping in the NCI-MATCH Trial (EAY131)

Key Points

Genomic alterations identified in patients demonstrate important distinctions based on treatment responses.
The analysis highlights ROS1 translocations in patients treated with crizotinib, indicating significant mutation presence.
Patients stratified according to best overall response show clear patterns of mutations in tissue and plasma DNA.
Findings underscore the potential for plasma DNA analysis in understanding tumor dynamics and treatment efficacy.

Abstract

Supplementary Figure 3. Genomic alterations detected in patients treated in subprotocol G enrolling patients with ROS1 translocations who received treatment with crizotinib. Patients are stratified according to the best overall response. Triangles are used to depict the presence of mutation in tissue (lower triangle) and/or plasma (upper triangle).

Supplementary Figure 3 from Concordance between Tumor Tissue and Plasma DNA Genotyping in the NCI-MATCH Trial (EAY131)

Key Points

Abstract

Cite This Study